Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Cash from Discontinued Operations (2016 - 2025)

Historic Cash from Discontinued Operations for AC Immune (ACIU) over the last 11 years, with Q3 2025 value amounting to -$140.8 million.

  • AC Immune's Cash from Discontinued Operations fell 21718.57% to -$140.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.2 million, marking a year-over-year decrease of 6735.66%. This contributed to the annual value of $61.7 million for FY2016, which is 3852.27% up from last year.
  • As of Q3 2025, AC Immune's Cash from Discontinued Operations stood at -$140.8 million, which was down 21718.57% from -$22.1 million recorded in Q1 2025.
  • In the past 5 years, AC Immune's Cash from Discontinued Operations ranged from a high of $120.2 million in Q3 2024 and a low of -$140.8 million during Q3 2025
  • Its 5-year average for Cash from Discontinued Operations is -$6.2 million, with a median of -$16.7 million in 2021.
  • Its Cash from Discontinued Operations has fluctuated over the past 5 years, first soared by 89814.59% in 2024, then crashed by 198096.22% in 2025.
  • Over the past 5 years, AC Immune's Cash from Discontinued Operations (Quarter) stood at -$15.8 million in 2021, then grew by 11.24% to -$14.0 million in 2022, then fell by 7.42% to -$15.1 million in 2023, then skyrocketed by 898.15% to $120.2 million in 2024, then tumbled by 217.19% to -$140.8 million in 2025.
  • Its last three reported values are -$140.8 million in Q3 2025, -$22.1 million for Q1 2025, and $120.2 million during Q3 2024.